Education
About Us
Working with TipRanks
Follow Us
Cullinan Management (CGEM)
NASDAQ:CGEM
CGEM Analyst Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CGEM Stock 12 Month Forecast
Average Price Target
$27.33
▲(312.84% Upside)
| Highest Price Target$34.00 | Average Price Target$27.33 | Lowest Price Target$22.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$24
Buy
262.54%
Upside
Reiterated
09/12/25
Promising Trial Results and Strategic Plans Justify Buy Rating for Cullinan ManagementValuation and Risks. We assess Cullinan using a discounted cash flow (DCF)-based valuation methodology, with a 70% probability of launch for zipalertinib in exon 20+ NSCLC and a 20% probability of launch for CLN-978 in SLE. In addition, we employ an 11% discount rate, a 29% effective tax rate, and a 1.0% terminal growth rate.
BTIG
$32
Buy
383.38%
Upside
Reiterated
09/09/25
Positive Buy Rating for Cullinan Management Driven by Promising Zipalertinib Trial Results in NSCLC with Uncommon EGFR MutationsWe also note that Tx-naive patients in this cohort had a substantially higher ORR rate (62.5% vs. 21.9% for patients with ≥1 prior line of Tx), further supporting zipalertinib uptake in earlier lines of Tx. Additional detailed data from the prior-amivantamab cohort in REZILIENT1 were also presented and similarly support zipalertinib's use case in earlier settings (patients receiving prior amivantamab only had a higher ORR vs. prior amivantamab + other ex20ins-targeted Tx). We continue to see the data supporting a strong use case for zipalertinib in this refractory Tx setting where there are limited ideal Tx options (discussed below).
William Blair
―
Buy
―
Reiterated
09/09/25
Promising Drug Pipeline and Strategic Collaborations Drive Buy Rating for Cullinan ManagementWe believe zipalertinib continues to show strong efficacy in previously treated (with both chemotherapy and Rybrevant) patients, which along with its favorable tolerability profile should bode well for potential uptake in the second-line setting (pending NDA submission planned by the end of 2025). Zipalertinib has also demonstrated encouraging initial activity in uncommon EGFR mutated NSCLC, which could support a meaningful expansion opportunity. We highlight in greater detail below the datasets and other relevant data points from Dizal Pharma’s Zegfrovy (sunvozertinib) and ArriVent’s (AVBP $19.87) firmonertinib, which have competitive read-through to zipalertinib.
Leerink Partners
―
Buy
―
Reiterated
09/04/25
Cullinan Management's Strategic Adjustments and Pipeline Development Justify Buy RatingWe spoke to management regarding the guidance change, which appears to be driven by slower enrollment due to certain eligibility criteria. To accelerate enrollment, the company has submitted an amended protocol with two key changes. First, the SLEDAI total score at screening will be lowered from ≥8 to ≥6. Second, the prior treatment criteria will be liberalized to allow for a less heavily pretreated population. Previously, patients needed to have inadequate response to at least two treatments, including at least one immunosuppressive or biologic SoC, and this has been revised to inadequate response to at least one immunosuppressant or biologic used to treat SLE.
JonesTrading
$34
Buy
413.60%
Upside
Reiterated
09/04/25
Morgan Stanley
$35→$28
Buy
322.96%
Upside
Reiterated
08/18/25
UBS
$24
Buy
262.54%
Upside
Reiterated
08/18/25
Clear Street
$22
Buy
232.33%
Upside
Reiterated
08/08/25
Stifel Nicolaus
$22
Buy
232.33%
Upside
Initiated
06/11/25
Wedbush
$23
Buy
247.43%
Upside
Reiterated
06/05/25
TR | OpenAI - 4o
―
Sell
―
Downgraded
05/01/25
AI Generated ArticleAI Generated Article
Guggenheim
$30
Buy
353.17%
Upside
Reiterated
02/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$24
Buy
262.54%
Upside
Reiterated
09/12/25
Promising Trial Results and Strategic Plans Justify Buy Rating for Cullinan ManagementValuation and Risks. We assess Cullinan using a discounted cash flow (DCF)-based valuation methodology, with a 70% probability of launch for zipalertinib in exon 20+ NSCLC and a 20% probability of launch for CLN-978 in SLE. In addition, we employ an 11% discount rate, a 29% effective tax rate, and a 1.0% terminal growth rate.
BTIG
$32
Buy
383.38%
Upside
Reiterated
09/09/25
Positive Buy Rating for Cullinan Management Driven by Promising Zipalertinib Trial Results in NSCLC with Uncommon EGFR MutationsWe also note that Tx-naive patients in this cohort had a substantially higher ORR rate (62.5% vs. 21.9% for patients with ≥1 prior line of Tx), further supporting zipalertinib uptake in earlier lines of Tx. Additional detailed data from the prior-amivantamab cohort in REZILIENT1 were also presented and similarly support zipalertinib's use case in earlier settings (patients receiving prior amivantamab only had a higher ORR vs. prior amivantamab + other ex20ins-targeted Tx). We continue to see the data supporting a strong use case for zipalertinib in this refractory Tx setting where there are limited ideal Tx options (discussed below).
William Blair
―
Buy
―
Reiterated
09/09/25
Promising Drug Pipeline and Strategic Collaborations Drive Buy Rating for Cullinan ManagementWe believe zipalertinib continues to show strong efficacy in previously treated (with both chemotherapy and Rybrevant) patients, which along with its favorable tolerability profile should bode well for potential uptake in the second-line setting (pending NDA submission planned by the end of 2025). Zipalertinib has also demonstrated encouraging initial activity in uncommon EGFR mutated NSCLC, which could support a meaningful expansion opportunity. We highlight in greater detail below the datasets and other relevant data points from Dizal Pharma’s Zegfrovy (sunvozertinib) and ArriVent’s (AVBP $19.87) firmonertinib, which have competitive read-through to zipalertinib.
Leerink Partners
―
Buy
―
Reiterated
09/04/25
Cullinan Management's Strategic Adjustments and Pipeline Development Justify Buy RatingWe spoke to management regarding the guidance change, which appears to be driven by slower enrollment due to certain eligibility criteria. To accelerate enrollment, the company has submitted an amended protocol with two key changes. First, the SLEDAI total score at screening will be lowered from ≥8 to ≥6. Second, the prior treatment criteria will be liberalized to allow for a less heavily pretreated population. Previously, patients needed to have inadequate response to at least two treatments, including at least one immunosuppressive or biologic SoC, and this has been revised to inadequate response to at least one immunosuppressant or biologic used to treat SLE.
JonesTrading
$34
Buy
413.60%
Upside
Reiterated
09/04/25
Morgan Stanley
$35→$28
Buy
322.96%
Upside
Reiterated
08/18/25
UBS
$24
Buy
262.54%
Upside
Reiterated
08/18/25
Clear Street
$22
Buy
232.33%
Upside
Reiterated
08/08/25
Stifel Nicolaus
$22
Buy
232.33%
Upside
Initiated
06/11/25
Wedbush
$23
Buy
247.43%
Upside
Reiterated
06/05/25
TR | OpenAI - 4o
―
Sell
―
Downgraded
05/01/25
AI Generated ArticleAI Generated Article
Guggenheim
$30
Buy
353.17%
Upside
Reiterated
02/28/25
Best Analysts Covering Cullinan Management
1 Month
xxx
Success Rate
5/12 ratings generated profit
Average Return
+4.38%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 41.67% of your transactions generating a profit, with an average return of +4.38% per trade.
3 Months
xxx
Success Rate
5/12 ratings generated profit
Average Return
+9.42%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of +9.42% per trade.
1 Year
Success Rate
5/12 ratings generated profit
Average Return
+21.38%
reiterated a buy rating last month
Copying Kaveri Pohlman's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +21.38% per trade.
2 Years
xxx
Success Rate
7/27 ratings generated profit
Average Return
-12.84%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 25.93% of your transactions generating a profit, with an average return of -12.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CGEM Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
9
13
12
14
12
Buy
5
11
9
9
7
Hold
2
1
0
0
0
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
17
26
22
23
19
Each month's total comprises the sum of three months' worth of ratings.
CGEM Financial Forecast
CGEM Stock Forecast FAQ
What is CGEM’s average 12-month price target, according to analysts?
Based on analyst ratings, Cullinan Management’s 12-month average price target is 27.33.
What is CGEM’s upside potential, based on the analysts’ average price target?
Cullinan Management has 312.84% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CGEM a Buy, Sell or Hold?
Cullinan Management has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
What is Cullinan Management’s price target?
The average price target for Cullinan Management is 27.33. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $34.00 ,the lowest forecast is $22.00. The average price target represents 312.84% Increase from the current price of $6.62.
The highest analyst price target is $34.00 ,the lowest forecast is $22.00. The average price target represents 312.84% Increase from the current price of $6.62.
What do analysts say about Cullinan Management?
Cullinan Management’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of CGEM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.